Access the full text.
Sign up today, get DeepDyve free for 14 days.
Major progress in the treatment of multiple myeloma has been made in the last several years. However, myeloma remains incurable and patients with high-risk cytogenetics or advanced stage disease have an even worsen survival. Only allogeneic transplantation may have curative potential in some patients. However, the high non-relapse mortality and incidence of chronic graft-versus-host disease have raised controversy regarding this procedure. In this review, we will address the role of upfront and delayed allogeneic transplant.
Oncology and Therapy – Springer Journals
Published: Jun 1, 2022
Keywords: Multiple myeloma; Allogeneic transplantation; Chronic graft-versus-host disease; CAR-T cell therapy
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.